TY  - GEN
AU  - Lynd,Larry D
AU  - Najafzadeh,Mehdi
AU  - Colley,Lindsey
AU  - Byrne,Michael F
AU  - Willan,Andrew R
AU  - Sculpher,Mark J
AU  - Johnson,F Reed
AU  - Hauber,A Brett
TI  - Using the incremental net benefit framework for quantitative benefit-risk analysis in regulatory decision-making--a case study of alosetron in irritable bowel syndrome
SN  - 1524-4733
PY  - 2010///0920
KW  - Carbolines
KW  - adverse effects
KW  - Computer Simulation
KW  - Drug and Narcotic Control
KW  - Drug-Related Side Effects and Adverse Reactions
KW  - Female
KW  - Gastrointestinal Agents
KW  - Humans
KW  - Irritable Bowel Syndrome
KW  - drug therapy
KW  - Male
KW  - Middle Aged
KW  - Patient Preference
KW  - Quality of Life
KW  - Risk Assessment
KW  - methods
KW  - Severity of Illness Index
N1  - Publication Type: Journal Article; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1111/j.1524-4733.2009.00595.x
ER  -